• Produktbild: Buprenorphine Therapy of Opiate Addiction
  • Produktbild: Buprenorphine Therapy of Opiate Addiction
- 10%

Buprenorphine Therapy of Opiate Addiction

10% sparen

107,99 € UVP 120,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

12.12.2012

Abbildungen

22 illus., schwarz-weiss Illustrationen

Herausgeber

Pascal Kintz + weitere

Verlag

Humana Press

Seitenzahl

168

Maße (L/B/H)

22,9/15,2/1 cm

Gewicht

254 g

Auflage

Softcover reprint of the original 1st ed. 2002

Sprache

Englisch

ISBN

978-1-4684-9713-7

Beschreibung

Rezension

Foreword by Albert D. Fraser

"This is a very useful and timely book in addiction medicine. . .This book details the use of buprenorphine with its risks and benefits. It draws extensively from available studies and literature, which are listed very clearly in tables. Some of the appendixes are especially useful for quick references. This is a very useful and easy to read book. It details the use of buprenorphine therapy as an alternate to methadone treatment. It also details the analytical advances in testing for buprenorphines. The book describes buprenorphine's pharmacology and current prescription practices in France. It also discusses the use of buprenorphine in various scenarios including in pregnant addicts, and provides a source of knowledge for everyone working in addiction medicine."-Doody's Health Sciences Book Review Journal

"This is a further volume in the growing Forensic medicine and Science Series edited by Steve Karch. This impressive series embraces a range of forensic topics. The style is now familiar, good topic editors with a broad spectrum of specialist authors contributing within their own area of expertise...good topic editors with a broad spectrum of specialist authors contributing within their own area of expertise....worthwhile reading for anyone in contact with patients who are opiate addicted." - Nil Aggrawal's Internet Journal of Forensic Medicine and Toxicology

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

12.12.2012

Abbildungen

22 illus., schwarz-weiss Illustrationen

Herausgeber

Verlag

Humana Press

Seitenzahl

168

Maße (L/B/H)

22,9/15,2/1 cm

Gewicht

254 g

Auflage

Softcover reprint of the original 1st ed. 2002

Sprache

Englisch

ISBN

978-1-4684-9713-7

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Buprenorphine Therapy of Opiate Addiction
  • Produktbild: Buprenorphine Therapy of Opiate Addiction
  • Chapter 1:
    Pharmacology of High-Dose Buprenorphine
    Pierre Marquet
    1 Introduction
    2 Pharmacokinetic Properties
    2.1 Absorption and Bioavailability
    2.2 Distribution
    2.3 Metabolism
    2.4 Excretion
    3 Pharmacodynamic Properties
    4 Administration Schedules
    5 Clinical Effects of Buprenorphine
    6 Conclusion
    References

    Chapter 2:
    Controlled Drug Administration Studies of High-Dose Buprenorphine in Humans
    Marilyn A. Huestis
    1 Introduction
    2 Bioavailability
    3 Dose-Effect Profiles
    4 Abuse Liability
    5 Toxicity
    6 Safety and Abuse Liability of High-Dose Intravenous Buprenorphine
    7 Conclusion
    References

    Chapter 3:
    High-Dose Buprenorphine for Treatment of Opioid Dependence
    Eric C. Strain
    1 Introduction
    2 Buprenorphine Solution vs Tablets
    3 Efficacy of Buprenorphine vs Placebo: Clinical Trials
    3.1 Summary of Placebo-Controlled Studies
    4 Efficacy of Buprenorphine vs Other Medications: Clinical Trials
    4.1 Summary of Studies Comparing Buprenorphine to Other Medications
    5 Safety and Side Effects of Buprenorphine
    6 Summary and Conclusions
    Acknowledgment
    References

    Chapter 4:
    Forseeable Advantages and Limits of Buprenorphine-Naloxone Association
    Michel Mallaret, Maurice Dematteis, Celine Villier, Claude Elisabeth Barjhoux, and Chantal Gatignol
    1 Introduction
    2 Advantages of Buprenorphine-Naloxone Association
    2.1Advantages of Opiate-Naloxone Association: Lessons of the Past
    2.1.1 Epidemic of Pentazocine and Tripelennamine Abuse in the United States
    2.1.2 Epidemic of Analgesic Buprenorphine Abuse in New Zealand
    2.2 Buprenorphine and Naloxone: A Complex and Controversial Pharmacology
    2.3 Clinical Aspects
    2.3.1 Pharmacokinetic/Pharmacodynamic Advantages of Associated Naloxone in BupNx Combination
    2.3.2 Sublingual Naloxone in BupNx TabletsDoes Not Decrease Buprenorphine Effects
    2.3.3 Sublingual Naloxone in BupNx Tablets Does Not Decrease Blockade Effects of Buprenorphine in Opioid-Dependent Patients
    2.3.4 Sublingual Naloxone in BupNx Tablets Does Not Precipitate Withdrawal Symptoms in Opioid-Dependent Patients
    2.3.5 Is the BupNx Combination Effective for Detoxification or Treatment of Depressive Symptoms in Opioid-Dependent Patients?
    2.3.6 What Is the Abuse Liability of Intravenous BupNx Combination in Nonopioid-Dependent and Opioid-Dependent Patients?
    2.3.7 Intravenous Naloxone May Decrease Respiratory Depression by Buprenorphine
    2.3.8 What Will Be the Epidemiological Consequences and Potential Economic Impact of the Use of BupNx Combination?
    3 Limits of Buprenorphine-Naloxone Association
    3.1 Potential Risk of Inefficacy of Naloxone in BupNx Combination
    3.2 Abuse Liability of Intravenous BupNx Combination: Low But Still Possible
    3.3 Adverse Buprenorphine Reactions and Sublingual BupNx Combination
    3.3.1 Respiratory Depression
    3.3.2 Involuntary Overdoses
    3.3.3 Experimental Buprenorphine Hepatotoxicity
    3.4 Specific Risks in Office-Based Treatment (BupNx Combination) of Opiate Dependence
    4 Conclusion
    References

    Chapter 5:
    Buprenorphine Maintenance Treatment in Primary Care: An Overview of the French Experience and Insight Into the Prison Setting
    Marc Deveaux and Jean Vignau
    1 Introduction
    2 Implementation of BMT Through French Primary Care System
    2.1 A Late But Considerable Concession to Harm Reduction Paradigm
    2.2 Legal Framework of Therapeutic Use of Buprenorphine
    2.2.1 Essential Landmarks of French Health Services
    2.2.2 Opioid Maintenance Treatments
    3 Observable Effects of French Policy
    3.1 Is BMT Accessible and Acceptable?
    3.2 Is BMT Safe?
    3.2.1 Data from Preregistration Studies
    3.2.2 Data from French Experience
    3.3 Is BMT Effective in Contr